Boan Biotech Begins International Phase III Trial Of Denosumab Biosimilars
One Product Is Already Approved For Marketing In China
Executive Summary
Having already launched one of its denosumab biosimilar products in China, Boan Biotech has now commenced an international Phase III study to secure approval in Europe, the US and Japan.
You may also be interested in...
Sandoz Follows US Denosumab Filing With European Acceptance
Sandoz has confirmed dual European filings for its denosumab biosimilar rival to Prolia and Xgeva, a few months after it submitted its candidate in the US.
Sandoz Faces US Denosumab Lawsuit Ahead Of Key 2025 Patent Expiry
Months after announcing that its GP2411 biosimilar denosumab candidate was accepted for filing by the FDA, Sandoz has been sued for alleged patent infringement by originator Amgen.
With Prolia Rival In The Bag, China’s Luye Takes Aim At Xgeva Biosimilar
Boan Biotech is continuing its ascent in Chinese biosimilars by filing another product with the country’s regulator.